← Human Trials & Peer-Reviewed Studies
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
Plain-language guide to PMID 23683069 (2013): double-blind randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 23683069
- Journal
- Diabetes, obesity & metabolism
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Hermansen K et al. (7 authors)
- DOI
- 10.1111/dom.12133
- Registered trial
- NCT00993304
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Liraglutide, published as a randomized controlled trial.
Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD).
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.
Each person switched between Liraglutide and the comparison at some point, usually with a gap in between.
After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC(0-8h)), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed.
What Was Measured
Topics PubMed links to this paper include Body Mass Index, Cardiovascular Diseases, Denmark, Diabetes Mellitus, Type 2, Diet, High-Fat, Gastric Emptying and Germany.
Author keywords: GLP-1 analogue, antidiabetic drug, lipid-lowering therapy, phase I-II study, randomized trial and type II diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.